Fifty-one of 300 patients undergoing high-dose chemotherapy with (n = 245) or without (n = 55) autologous stem cell rescue developed central venous catheter-related thrombosis diagnosed by Doppler sonography or contrast venography. Eighteen of these individuals underwent regional thrombolysis defined as the infusion of urokinase into a superficial vein of the ipsilateral upper extremity in a dose not sufficient to produce systemic fibrinolysis by laboratory criteria.
Summary: Fifty-one of 300 patients undergoing high-dose chemotherapy with (n = 245) or without (n = 55) autologous stem cell rescue developed central venous catheter-related thrombosis diagnosed by Doppler sonography or contrast venography. Eighteen of these individuals underwent regional thrombolysis defined as the infusion of urokinase into a superficial vein of the ipsilateral upper extremity in a dose not sufficient to produce systemic fibrinolysis by laboratory criteria.
Urokinase was administered at a dose of 75,000-150,000 U/hour for 24 to 96 hours and contrast venography was performed to assess response. All individuals had a partial or complete resolution of clinical signs and symptoms. Fifty percent of patients also achieved a partial radiographic response defined as clot lysis with irregular canalization of the vein. Therapeutic doses of heparin for 5 to 7 days and warfarin for at least 3 months were commenced at the conclusion of urokinase therapy. Twelve catheters were salvaged and utilized subsequently until no longer required. Six catheters were removed because of poor catheter function or rethrombosis. The median interval from diagnosis of the thrombus until extraction of the 12 salvaged catheters was 3 months (range 1-8 months). Only a single patient who developed gastrointestinal bleeding required discontinuation of urokinase. Regional thrombolysis is safe, easy to administer, effective in many instances, less costly than the doses of antifibrinolytic agents required to induce systemic fibrinolysis, and should be considered in patients receiving high-dose chemotherapy with autologous stem cell rescue who develop central venous catheter-related thrombosis. Key Words: Regional thrombolysis&mdash;Urokinase&mdash;Catheter&mdash;related thrombosis.
Central venous catheters (CVCs) are a fundamental component of the care of individuals undergoing bone marrow transplantation and high-dose chemotherapy with autologous peripheral blood stem cell rescue (PBSCR). They allow the administration of chemotherapeutic agents centrally to avoid peripheral phlebitis and also enable delivery of total parenteral nutrition, antibiotics, and blood transfusions. Furthermore, CVCs decrease both physical and emotional trauma due to repeated venipunctures over extended periods of time. Unfortunately, central venous catheter-related thrombosis (CVCT) is a frequent and therapeutically challenging complication in such individuals and has been reported to occur in up to 40% of cases (1) . Removal of the CVC may be required depending on the severity of symptoms as well as the future clinical needs of the patient. However, removal of the catheter results in loss of venous access and the subsequent need to place a second device. , To avoid discomfort, expense, and therapeutic delay due to removal and replacement of the CVC, both antithrombotic and fibrinolytic agents have been used to salvage the catheter. Both types of treatment pose special risks in patients with cancer or those undergoing high-dose chemotherapy with PBSCR because such individuals develop severe thrombocytopenia quite frequently. A standardized approach to the treatment of CVCT does not exist despite its frequency. We treated patients undergoing high-dose chemotherapy with or without PBSCR in a uniform manner to determine the safety and efficacy of regional thrombolysis with urokinase (Abbot Laboratories, North Chicago, IL, U.S.A.) infusion therapy.
MATERIALS AND METHODS
Three hundred consecutive patients identified between March 1993 and June 1997 at the University of Connecticut Health Center, Farmington, CT, were eligible for evaluation. Clinical data were obtained from compre- hensive chart reviews ( Table 1 ). The underlying malignancies included carcinoma of the breast (n = 145), non-Hodgkin's lymphoma and Hodgkin's disease (n = 91), multiple myeloma (n = 21 ), acute leukemia (n = 16), ovarian carcinoma (n = 11 ), and other solid tumors (n = 16). All 300 patients received one or more cycles of stem cell mobilization chemotherapy consisting of etoposide alone 60 mg/kg intravenously (40 patients, 42 cycles), etoposide 60 mg/kg intravenously and cyclophosphamide 3 G/M2 intravenously (19 patients, 21 courses), or etoposide 60 mg/kg intravenously, cyclophosphamide 3 G/M2 intravenously, and paclitaxel 200 mg/m2 intravenously (241 patients, 561 courses). These cycles of stem cell mobilization chemotherapy were administered at monthly intervals beginning 30 to 120 days prior to high-dose chemotherapy with autologous PBSCR. Fifty-five patients were ruled ineligible for PBSCR because of disease progression or intolerance of chemotherapy. The remaining 245 individuals received conditioning chemotherapy consisting of busulfan 16 mg/kg, orally, thiotepa 500 to 700 Mg/M2 intravenously, and carboplatin 800 to 1,000 Mg/M2 intravenously (n = 150); busulfan 16 mg/kg orally, cyclophosphamide 90 mg/kg intravenously, and etoposide 60 mg/kg intravenously (n = 91 ); or other regimens (n = 9) followed by autologous PBSCR.
Central venous access was obtained with a 13.5
French dual-lumen Hickman catheter (n = 265) (Bard Access Systems, Salt Lake City, UT, U.S.A.) inserted into the subclavian vein by a vascular surgeon, or a peripherally-inserted central catheter (n = 35) (Cook Inc., Bloomington, IN, U.S.A.) placed in the basilic vein under fluoroscopy by a radiologist (HHC). The catheter was inserted prior to the first course of stem cell mobilization chemotherapy and was retained for 60 to 90 days following PBSCR unless earlier removal was necessi-tated by a complication. During this period, the catheter was accessed frequently by patients, home care companies, and bone marrow transplant nurses. Warfarin, 1 mg orally once daily, was initiated on the day of CVC insertion and was continued until catheter removal unless it was held because the prothrombin became prolonged. Vancomycin 1 g intravenously was administered immediately prior to catheter insertion. All lumens were flushed with heparin 200 to 2,000 U daily depending on the size of the catheter. Catheter occlusion defined as an inability to withdraw blood was treated initially with 5,000 to 10,000 U of urokinase in each lumen. Failure of this maneuver prompted the initiation of a low-dose urokinase infusion 200 units/kg/hour for 2 to 6 hours through the malfunctioning lumen.
A diagnosis of CVCT was suspected clinically and confirmed by Doppler sonography or contrast venography. Fifty-one patients developed thrombosis of whom 25 received antithrombotic agents only. Eight patients were treated with systemic thrombolysis followed by therapeutic anticoagulation. Eighteen individuals received regional thrombolysis defined as the infusion of urokinase via a 1-inch long 20-gauge catheter (Protectiv Plus IV Catheter, Johnson and Johnson Medical Inc., Arlington, TX, U.S.A.) in a peripheral vein of the ipsilateral hand in a dose not sufficient to produce systemic fibrinolysis by laboratory criteria. A thrombin time was measured 4 hours after the initiation of thrombolytic therapy with an aim to keep it < 1.3 times the control value, the basis for which was entirely empiric.
The response to therapy was assessed by contrast venography performed 24 to 48 hours following the initiation of urokinase. Urokinase was discontinued immediately prior to the venogram and was reinstituted for a further period of 24 to 48 hours if the response was partial. Complete response was defined as total clot lysis and complete venous recanalization. Partial response was defined as >50% clot lysis with irregular canalization of the vein. No response was defined as incomplete clot lysis with failure to recanalize the vein.
The urokinase infusion was continued for 24 to 96 hours following which heparin was administered for 5 to 7 days to keep the activated partial thromboplastin time at 1.5 times the control value. Warfarin was initiated with heparin and continued until removal of the catheter. The aim of anticoagulation with warfarin was to keep the international normalized ratio (INR) between 2 and 3.
Major hemorrhage was defined as intracranial, retroperitoneal, overt, and associated with the need for red blood cell transfusions, or that which resulted in mortality. Minor hemorrhage included all other instances of bleeding. > ..
RESULTS

Clinical features
Fifty-one patients (17%) developed documented CVCT. Eighteen of these patients received regional thrombolysis for their CVCT and are the subject of this analysis. The clinical characteristics of these individuals are presented in Table 2 . Fourteen patients had a Hickman catheter whereas four individuals had a peripherally inserted central catheter. The CVC had been in place for a median of 46 days (range 3 to 180 days) prior to the documentation of thrombosis. The diagnosis of CVCT was established by upper extremity venography in 13 patients and by Doppler sonography in 5 individuals. Regional thrombolysis was administered through the CVC in three patients. The remaining individuals received urokinase via a peripheral venous catheter inserted in the ipsilateral hand. The median dose of urokinase was 75 000 U/hour (range 75,000 to 150,000 U/hour) by continuous intravenous infusion for a median duration of 48 hours (range 24 to 96 hours).
Response and outcome
The presenting signs and symptoms included upper extremity edema (n = 13), pain (n = 5), neck edema (n = 3), dysphagia (n = 2), and catheter malfunction (n = 2). A complete clinical response was evident in eight patients (44%) whereas a partial resolution of symptoms was observed in ten individuals (56%) by the end of the urokinase infusion. Follow-up contrast venography demonstrated a partial response in nine patients (50%). Five of these individuals had a >75% lysis of their thrombus. The remaining patients had minimal or no significant change (Table 3 ). Four patients developed a second CVCT 13 days, 16 days, 48 days, and 54 days, respectively, after the initial episode of thrombosis. The INR was subtherapeutic in all four patients. The second episode of CVCT was treated successfully with regional thrombolysis in one individual. However, the CVC in the TABLE 3 . Response to regional thrombolysis remaining three patients and in two nonresponders to initial thrombolysis were removed. Moreover, an additional patient dislodged and pulled out her catheter inadvertantly. The median duration for which the CVC were retained in the remaining 12 patients was 3 months (range 1 to 8 months). The catheters were removed only when no longer a necessary part of management.
Complications A prolongation of the thrombin time requiring a downward adjustment of the dose of urokinase was seen in 3 of 12 patients in whom it was measured. Four individuals developed hemorrhagic complications consisting of sanguinous oozing from the catheter site or minor hematoma formation. One of these patients also manifested major gastrointestinal bleeding in spite of a normal thrombin time and required discontinuation of thrombolytic therapy. There was no mortality.
DISCUSSION
Axillary and subclavian vein thrombosis accounts for 1 % to 4% of all deep vein thromboses (2, 3) and CVCTs comprise 30% to 40% of axillary and subclavian vein thromboses (3, 4) . The incidence of thrombosis with CVC ranges from 4.7% to 45.5% (1, (5) (6) (7) (8) (9) (10) (11) . Moreover, the incidence of deep vein thrombosis is greater with Hickman catheters compared to totally implanted devices (12) . In recipients of bone marrow or peripheral blood stem cells where Hickman catheters are a mainstay of treatment, the incidence of CVCT varies form 10.6% to 33% (13) (14) (15) . Two types of catheter-related thrombi, fibrin-sleeve and mural thromboses, have been identified (16) . Risk factors for the development of CVCT include duration of catheter use (16) , reduced antithrombin III level prior to catheter insertion (1), intrathoracic tumor (1), suboptimal home care of the catheter (1), abnormal Doppler sonography prior to catheter placement (17) , use of the left subclavian vein as the site of catheter insertion (8) , prior difficulty with blood withdrawal (8) , insertion of the CVC immediately following bone marrow harvesting (18) , increased number of lumens (14) , elevated platelet count (19) , presence of more than one CVC (13) , and catheter-sepsis (9) .
Clinical features of CVCT consist of pain, swelling, venous gangrene, superior vena caval syndrome and brachial plexopathy (20) . The incidence of pulmonary embolism following axillary and subclavian vein thrombosis ranges from 7.4% to 20% (20, 21) . Up to 23% of patients develop long-term symptoms related to the CVCT (20) . Prophylaxis against CVCT with warfarin 1 mg orally daily has been shown to decrease the incidence of thrombosis from 37.5% to 9.5% in one study of patients receiving conventional doses of chemotherapy (22) . Furthermore, the prophylactic use of dalteparin 2,500 U/day subcutaneously reduced the incidence of CVCT from 62% to 6% in another group of cancer patients receiving chemotherapy (19) . Catheter occlusions can be treated successfully with intraluminal urokinase incubation or low-dose infusion of thrombolytic agents (23, 24) .
More recently, thrombolysis has been attempted in an effort to recanalize the thrombosed vessels. Thrombolysis is recommended within 7 days of the onset of symptoms and must be followed by therapeutic anticoagulation for at least 6 to 12 weeks (20) , and preferably for the life of the CVC. Systemic thrombolysis can induce complete venographic clot lysis in 54% of patients (20) . Furthermore, only 15% of patients with CVCT undergoing systemic thrombolysis have persistent symptoms (20) . However, the doses of agents used in systemic thrombolysis are costly and may be associated with significant hemorrhagic complications, particularly in patients receiving high-dose chemotherapy with the associated thrombocytopenia and mucosal damage. The use of low doses of thrombolytic agents infused directly into the intramural thrombus or into the superficial venous system of the ipsilateral upper extremity can result in lysis of the clot in over 80% and up to 60% of patients, respectively (25) (26) (27) (28) (29) (30) . However, individuals undergoing high-dose chemotherapy and autologous PBSCR may not only be severely pancytopenic and immunocompromised, but may also require intravenous antibiotics and hyperalimentation and blood product support on a daily basis. Furthermore, such patient are restricted to the confines of a relatively aseptic environment and may be intolerant of lengthy invasive procedures in a radiology suite. Therefore, even though direct intramural clot lysis is the technique with the highest response rates (29), regional thrombolysis as administered in our patients appears to be a safe and reasonable alternative.
This study represents one of the largest series of patients undergoing regional thrombolysis. The use of a regional infusion of low-dose urokinase for 48 to 72 hours can lead to a rapid resolution of clinical symptoms and signs in most patients and a significant radiographic response in half of the individuals. Moreover, the incidence of adverse reactions is low and the catheter can be salvaged for further use in nearly two-thirds of all patients. Additionally, there is a potential for significant cost-reduction compared to systemic thrombolysis.
